Ideal Power Announces Fabrication of First Double-Sided

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ideal Power Announces Fabrication of First Double-Sided B-TRAN(TM) Power Semiconductor Devices

AUSTIN, TX--(Marketwired - Oct 20, 2016) - Ideal Power Inc. ( NASDAQ : IPWR ), a developer of innovative power conversion technologies, is announcing today that its semiconductor foundry partner has successfully completed the fabrication of prototypes of Ideal Power's Bi-Directional Bi-Polar Junction TRANsistor (B-TRAN™). Ideal Power holds over 20 patents on the B-TRAN™ including patents on the unique double handle wafer process that was used to produce the initial devices. 

Due to its anticipated low conduction and switching losses, Ideal Power believes that the B-TRAN™ has the capability to improve the efficiency of a range of power control and conversion equipment, such as variable frequency drives, solar PV inverters, bi-directional energy storage and microgrid power conversion systems, electric vehicle drivetrains, solid-state DC and AC contactors, and other power conversion products. IHS Technology projects that the power semiconductor market will be over $20 billion by 2019. Ideal Power expects the performance advantages of B-TRAN™ to enable it to address a significant portion of the power semiconductor market that currently relies on power semiconductor devices such as Integrated-Gate Bipolar Transistors (IGBTs).

"The fabrication of the first B-TRAN™ devices is a critical step in our efforts to commercialize this unique technology. The B-TRAN™, due to its unique double-sided structure, is expected to deliver substantial performance improvements over today's power semiconductor devices in bi-directional power control applications," said Bill Alexander, CTO of Ideal Power and co-inventor of the B-TRAN™. "Currently, four conventional switches (two IGBTs and two diodes) are required to control power bi-directionally. We believe that the B-TRAN™ will be able to perform the same function with efficiency losses predicted to be 1/10th that of conventional switches. Additionally, the faster switching performance predicted for the B-TRAN™ should result in more efficient, smaller and lower cost power converters."

Earlier this year, Ideal Power announced that first silicon test results by its semiconductor foundry validated key characteristics of its B-TRAN™ technology. The test results can be found in the company's updated B-TRAN™ White Paper. The results confirmed central B-TRAN™ elements and operational modes and were consistent with third party device simulations that predicted significant performance and efficiency improvements over conventional power switches such as SCRs, IGBTs and MOSFETs.

The B-TRAN™ devices produced by Ideal Power's fabricator are not production-ready devices and will be used to test and characterize the capabilities of the B-TRAN™. Ideal Power will package these initial devices with supporting drive circuitry for testing and characterization which is expected to begin later this year. The results of this testing will be used to optimize the device design and manufacturing process. The first commercial use of the devices is expected to be in Ideal Power's PPSA-based converters.

About Ideal Power Inc. Ideal Power Inc. ( NASDAQ : IPWR ) is a technology company dedicated to advancing the efficiency of electric power conversion. The company has developed a novel, patented power conversion technology called Power Packet Switching Architecture™ ("PPSA"). PPSA improves the size, cost, efficiency, flexibility and reliability of electronic power converters. PPSA can scale across several large and growing markets, including solar PV, variable frequency drives, battery energy storage, mobile power and microgrids, and electric vehicle charging. The Company is also developing and has patented a bi-directional, bi-polar junction transistor ("B-TRAN™") which has the potential to dramatically increase bi-directional power switching efficiency and power density. Ideal Power employs a capital-efficient business model which enables the company to address several product development projects and markets simultaneously. For more information, visit www.IdealPower.com .

Safe Harbor Statement All statements in this release that are not based on historical fact are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Specific forward-looking statements include our comments about expected performance of B-TRAN™ devices, potential technical advantages of the B-TRAN™ devices compared to competing technologies, potential markets we could address with our B-TRAN™ technology, that the B-TRAN™ is expected to be able to address a significant portion of the power semiconductor market that currently relies on power semiconductor devices such as Integrated-Gate Bipolar Transistors and the expected timing of the testing of the first B-TRAN™ devices. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, whether the patents for our technology provide adequate protection and whether we can be successful in maintaining, enforcing and defending our patents, whether a demand for energy storage products will grow, whether demand for our products, which we believe are disruptive, will develop and whether we can compete successfully with other manufacturers and suppliers of energy conversion products, both now and in the future, as new products are developed and marketed. The B-TRAN™ is a new and novel technology, and the fabricated devices described in this press release have not been subjected to performance testing. We may encounter difficulties manufacturing the B-TRAN™ (or having the B-TRAN™ manufactured) in commercial quantities with acceptable margins or at all, and commercially manufactured B-TRAN™ devices may not achieve the technical performance improvements we expect based on preliminary tests conducted to date. There are risks that the device might not achieve market acceptance in these markets. In addition, competitors may offer products based upon competing technologies that outperform the B-TRAN™. The costs of manufacturing, marketing and selling the B-TRAN™ may exceed our expectations so that we may not realize acceptable, or any, profit margins related to B-TRAN™ sales or license revenue. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Ideal Power Media Contact: Mercom Communications www.mercomcapital.com Wendy Prabhu Email Contact 1.512.215.4452 Ideal Power Inc. Investor Relations Contact: MZ North America www.mzgroup.us Matt Hayden Email Contact 1.949.259.4986

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 120

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 99

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 710

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 20

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Wuliangye Aims for Global Branding Boost at Panda Event

Updated Category News Views 179

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 312

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 474

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Updated Category News Views 134

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Traditions Bancorp Declares New Cash Dividend for Investors

Updated Category News Views 76

Traditions Bancorp Declares Quarterly Cash Dividend On a recent date, the Board of Directors of Traditions Bancorp (OTC: TRBK), the parent company of Traditions Bank, announced a quarterly cash dividend of eight cents per common share. This dividend reflects the company's strong commitment to returning value to its shareholders and will be disbursed shortly. The payment...

Continue Reading
LONGi BC Tech Paves the Way for Solar Leadership in Europe

Updated Category News Views 334

LONGi's Impact on Europe's Solar Industry LONGi, recognized as a leader in solar technology, has made remarkable strides in reshaping the renewable energy scene in Europe. With an impressive 10GW of back contact (BC) modules deployed, the continent is rapidly becoming a hotbed for high-efficiency solar solutions. This accomplishment underlines the company's crucial...

Continue Reading
PACS Group Investors: Important Actions to Take Now

Updated Category News Views 152

Important Deadline for PACS Group Investors Investors in PACS Group, Inc. are advised to take note of an important lead plaintiff application deadline related to recent securities class action lawsuits. If you have incurred losses exceeding $100,000 in the company's stock, you may be eligible to participate in these legal proceedings. Class Action Lawsuit Details The...

Continue Reading
Exploring Market Sentiment Around Morningstar Inc and Its Trends

Updated Category News Views 207

Understanding Morningstar Inc's Market Position Morningstar Inc (NYSE:MORN) has recently shown a notable decline in its short interest, with a decrease of 9.22% reported. Currently, there are approximately 655 thousand shares sold short, constituting about 2.56% of the total shares available for trading. This information is pivotal for investors since it reflects the...

Continue Reading
Julie Springer Expands Legal Services with Mediation Practice

Updated Category News Views 363

Julie Springer's New Ventures in Mediation In the dynamic legal scene of Austin, seasoned attorney Julie A. Springer is making waves by broadening her practice to include mediation and arbitration services. This thoughtful transition reflects her long-time dedication to effectively settling business disputes, educational conflicts, and employment issues. Professional...

Continue Reading